Sign in Subscribe
COVID-19

Boosting Immunity: Understanding the Role of mRNA COVID-19 Vaccines

Strategic Insights

— 2 min read

The Centers for Disease Control and Prevention (CDC) has recommended an additional dose of mRNA COVID-19 vaccine for people who are moderately to severely immunocompromised. This recommendation is based on the effectiveness of messenger RNA (mRNA) vaccines, such as those developed by Pfizer Inc. and Moderna Inc., in providing instructions to cells to make harmless spike proteins. The immune system then recognizes the spike proteins and produces antibodies, which can neutralize the SARS-CoV-2 virus.

Key Takeaways:

  • The CDC recommends an additional dose of mRNA COVID-19 vaccine for people who are moderately to severely immunocompromised, including those with weakened immune systems or undergoing chemotherapy.
  • The mRNA vaccines instruct cells to make harmless spike proteins, which are then recognized by the immune system and produce antibodies that can neutralize the SARS-CoV-2 virus.
  • The immune system's response to the vaccine is amplified by repeated exposure, such as through booster shots, which can generate a stronger response against the virus.
  • The COVID-19 mRNA vaccines provide short-term protection, and a third or booster shot is needed to achieve longer-lasting immunity.
  • The UC Davis Medical Center is participating in a global clinical trial to investigate the efficacy and side effects of the COVID-19 mRNA vaccine manufactured by Pfizer Inc. and BioNTech SE.
  • The trial involves 60 volunteers who have returned for a booster shot trial, with half receiving a placebo and the other half receiving the Pfizer vaccine.
  • The process of collecting multifactorial data, including antibody levels, infection levels, and reactivity to the third dose, has been remarkably straightforward.
  • Researchers are still waiting for the interim analysis of the booster trial to be released by Pfizer Inc. and hope that the results will confirm the effectiveness of a third shot.
  • Participation in clinical trials is crucial in understanding how vaccines work and how to improve their effectiveness.

Statistics:

  • 60 volunteers have returned for the booster trial out of 225 who initially participated in the clinical trial.
  • The trial is a one-year, double-blind, placebo-controlled study, with half of the participants receiving a placebo and the other half receiving the Pfizer vaccine.
  • The booster shot is made up of the exact same components and dosage as the original Pfizer vaccine.
  • The researchers are following the participants' antibody levels, infection levels, and reactivity to the third dose to determine the efficacy of the booster shot.
  • It is estimated that the Pfizer vaccine has been given to approximately 1 billion people worldwide.
  • The risks associated with the vaccine are incredibly small, while the benefits are incredibly large.

Sources:

  • Centers for Disease Control and Prevention (CDC)
  • Dr. Timothy Albertson, Professor and Chair of Internal Medicine at UC Davis Health
  • Dr. Angela Haczku, Associate Dean for Translational Research at UC Davis Health
  • Gabby Echt, Clinical Research Coordinator at UC Davis Medical Center
  • UC Davis Health
  • Article published by UC Davis Health
  • Pfizer Inc.
  • BioNTech SE
  • Legal Monitor Worldwide
  • SyndiGate Media Inc.

Read more